Profile
Paul M.
Schneider is currently the Chief Financial Officer at Freeline Therapeutics Holdings Plc.
Prior to his current position, he served as the Senior Vice President-Finance at Casebia Therapeutics LLC from 2016 to 2019.
He also held the position of Senior Vice President-Finance & Operations at Exo Therapeutics, Inc. Mr. Schneider completed his undergraduate degree at Boston College.
Paul Schneider active positions
| Companies | Position | Start |
|---|---|---|
| FREELINE THERAPEUTICS HOLDINGS PLC | Director of Finance/CFO | 2022-05-15 |
Former positions of Paul Schneider
| Companies | Position | End |
|---|---|---|
Casebia Therapeutics LLC
Casebia Therapeutics LLC Pharmaceuticals: GenericHealth Technology Discovers, develops and commercializes gene-editing therapeutics to treat the genetic causes of bleeding disorders, autoimmune disease | Corporate Officer/Principal | 2019-08-31 |
Exo Therapeutics, Inc.
Exo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs and small-molecule enzyme inhibitor discovery platform that targets distal binding pockets of enzymes | Director of Finance/CFO | - |
Training of Paul Schneider
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 4 |
|---|---|
Boston College
Boston College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Casebia Therapeutics LLC
Casebia Therapeutics LLC Pharmaceuticals: GenericHealth Technology Discovers, develops and commercializes gene-editing therapeutics to treat the genetic causes of bleeding disorders, autoimmune disease | Health Technology |
Exo Therapeutics, Inc.
Exo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs and small-molecule enzyme inhibitor discovery platform that targets distal binding pockets of enzymes | Health Technology |
Freeline Therapeutics Holdings Plc
Freeline Therapeutics Holdings Plc BiotechnologyHealth Technology Develops and manufactures next-generation gene therapies | Health Technology |
- Stock Market
- Insiders
- Paul Schneider
















